6 Biotechnology Stocks to Sell Now

Advertisement

This week, the ratings of 6 Biotechnology stocks on Portfolio Grader are down. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).

FibroGen, Inc. (FGEN) earns a D this week, moving down from last week’s grade of C. The company also gets F’s in earnings revisions and return on equity. For more information, get Portfolio Grader’s complete analysis of FGEN stock.

Osiris Therapeutics, Inc. (OSIR) slips from a D to a F this week. Osiris Therapeutics, Inc. researches and develops therapeutic products for the regeneration of human connective tissues. The company also gets F’s in earnings growth, earnings revisions, and earnings surprise. For more information, get Portfolio Grader’s complete analysis of OSIR stock.

Mesoblast Limited Sponsored ADR’s (MESO) rating weakens this week, dropping to a F versus last week’s D. The company also gets F’s in earnings surprise and return on equity. For more information, get Portfolio Grader’s complete analysis of MESO stock.

Strongbridge Biopharma plc (SBBP) gets weaker ratings this week as last week’s C drops to a D. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of SBBP stock.

Cerulean Pharma, Inc. (CERU) is having a tough week. The company’s rating falls from a D to a F. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of CERU stock.

This week, Galectin Therapeutics Inc.’s (GALT) rating worsens to a F from the company’s D rating a week ago. Galectin Therapeutics Inc. is a drug development company. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of GALT stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.


Article printed from InvestorPlace Media, https://investorplace.com/2016/02/6-biotechnology-stocks-to-sell-now-3/.

©2024 InvestorPlace Media, LLC